Kaken Pharmaceutical Co Ltd
OTC:KKPCF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kaken Pharmaceutical Co Ltd
OTC:KKPCF
|
JP |
|
M
|
Maximus Resources Ltd
F:M5F
|
AU |
|
Beam Global
F:16NA
|
US |
|
C
|
Casing Macron Technology Co Ltd
TPEX:3325
|
TW |
|
A
|
Ayala Corp
OTC:AYALY
|
PH |
|
C
|
Cantex Mine Development Corp
F:DHD1
|
CA |
|
Nihon Yamamura Glass Co Ltd
TSE:5210
|
JP |
Wall St Price Targets
KKPCF Price Targets Summary
Kaken Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for KKPCF is 29.8 USD with a low forecast of 26.23 USD and a high forecast of 36.13 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is KKPCF's stock price target?
Price Target
29.8
USD
According to Wall Street analysts, the average 1-year price target for KKPCF is 29.8 USD with a low forecast of 26.23 USD and a high forecast of 36.13 USD.
What is the Revenue forecast for Kaken Pharmaceutical Co Ltd?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Revenue has been -1%. The projected CAGR for the next 3 years is 3%.
What is the Gross Profit forecast for Kaken Pharmaceutical Co Ltd?
Projected CAGR
0%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 2 years is 0%.
What is the Pre-Tax Income forecast for Kaken Pharmaceutical Co Ltd?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -13%. The projected CAGR for the next 2 years is 3%.
What is the Net Income forecast for Kaken Pharmaceutical Co Ltd?
Projected CAGR
-1%
Over the last 13 years, the compound annual growth rate for Net Income has been -10%. The projected CAGR for the next 2 years is -1%.
